CalciMedica, Inc. (NASDAQ:CALC) Sees Significant Decline in Short Interest

CalciMedica, Inc. (NASDAQ:CALC - Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 34,200 shares, a decrease of 9.3% from the September 30th total of 37,700 shares. Approximately 0.8% of the shares of the company are short sold. Based on an average daily volume of 35,500 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CALC. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of CalciMedica in a research report on Tuesday, August 13th. Oppenheimer upped their price objective on shares of CalciMedica from $14.00 to $20.00 and gave the stock an "outperform" rating in a report on Wednesday, July 10th.

Insiders Place Their Bets

In related news, Director Robert N. Wilson acquired 54,000 shares of the firm's stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $3.72 per share, for a total transaction of $200,880.00. Following the completion of the acquisition, the director now directly owns 364,196 shares of the company's stock, valued at approximately $1,354,809.12. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders bought 65,000 shares of company stock worth $243,120. Insiders own 53.30% of the company's stock.

CalciMedica Stock Up 22.1 %

NASDAQ:CALC traded up $0.87 during trading hours on Wednesday, hitting $4.80. 266,117 shares of the stock were exchanged, compared to its average volume of 31,545. CalciMedica has a twelve month low of $2.14 and a twelve month high of $8.38. The company has a market capitalization of $51.60 million, a P/E ratio of -2.23 and a beta of 1.27. The company's 50 day moving average is $4.27 and its two-hundred day moving average is $4.64.

CalciMedica (NASDAQ:CALC - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.03. On average, equities research analysts expect that CalciMedica will post -2.21 EPS for the current year.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.